Communiqués Keenova Therapeutics plc Deutsche Boerse AG

Actions

MCD0

IE000O3L0NQ3

Produits pharmaceutiques

Temps Différé Deutsche Boerse AG 08:16:42 15/11/2023			Varia. 5j.	Varia. 1 janv.
0,0200 ^EUR	-66,94%		-.--%	-

01/09	Keenova Therapeutics lance DC Hand Anatomy, une expérience éducative en réalité mixte sur la maladie de Dupuytren	CI
20/08	Keenova Therapeutics plc administre la première dose dans le cadre de l'essai de phase 3 du Xiaflex pour l'orteil en marteau	CI

Communiqués

22/12/23	Mallinckrodt Announces Journal Publication of Economic Evidence for TERLIVAZ for Injection in Adults with Hepatorenal Syndrome	AQ
08/12/23	Mallinckrodt Announces FDA Clearance of the INOmax EVOLVE DS Delivery System and Approval of the INOmax Mini-Cylinder	AQ
09/11/23	Mallinckrodt to Present Breadth of Data on TERLIVAZ for Injection in Adult Patients with Hepatorenal Syndrome at the American Association for the Study of Liver Diseases 2023 Liver Meeting	AQ
07/11/23	Mallinckrodt: Q3 Earnings Snapshot	AQ
02/11/23	Mallinckrodt to Present Data on TERLIVAZ for Injection in Adult Patients with Hepatorenal Syndrome at the American Society of Nephrology Kidney Week 2023 Scientific Meeting	AQ
23/10/23	Mallinckrodt to Present Data on TERLIVAZ for Injection in Adult Patients with Hepatorenal Syndrome at the American College of Gastroenterology Annual Scientific Meeting	AQ
01/09/23	Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit, Hyperactivity Disorder	AQ
30/08/23	Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations	PR
10/08/23	Mallinckrodt plc Reports Second Quarter 2023 Financial Results and Reaffirms Full Year Guidance	AQ
09/08/23	Mallinckrodt: Q2 Earnings Snapshot	AQ
21/06/23	MALLINCKRODT PLC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
16/06/23	Mallinckrodt to Present Data on TERLIVAZ for Injection in Adult Patients with Hepatorenal Syndrome at the European Association for the Study of the Liver Congress 2023	AQ
09/05/23	Mallinckrodt: Q1 Earnings Snapshot	AQ
09/05/23	MALLINCKRODT PLC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
28/04/23	Buxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding Failure to Address Evidential Multibillion-Dollar Asset Value Depreciation Expense Concealment Scheme	BU
25/04/23	Mallinckrodt to Report Earnings Results for First Quarter 2023	AQ
22/03/23	Mallinckrodt to Present New Retrospective Data on Effect of Acthar Gel to Reduce Corticosteroid Use and Burden for Advanced Sarcoidosis at the Academy of Managed Care Pharmacy 2023 Annual Meeting	AQ
10/03/23	Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX Extracorporeal Photopheresis System for the Treatment of Chronic Graft Versus Host Disease	AQ
07/03/23	MALLINCKRODT PLC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
03/03/23	MALLINCKRODT PLC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
01/03/23	Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance	AQ
28/02/23	Mallinckrodt: Q4 Earnings Snapshot	AQ
17/02/23	Mallinckrodt to Present at Cowen's 43rd Annual Health Care Conference	AQ
09/02/23	Mallinckrodt to Report Earnings Results for Fourth Quarter 2022	AQ
13/01/23	Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer	AQ